Compounds > 15-amino-4,7,10,13-tetraoxapentadecanoic acid
Page last updated: 2024-11-13

15-amino-4,7,10,13-tetraoxapentadecanoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

15-amino-4,7,10,13-tetraoxapentadecanoic acid: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID22731902
SCHEMBL ID515661
MeSH IDM0505382

Synonyms (45)

Synonym
AKOS016013569
BP-20423
amino-peg4-acid
3,6,9,12-tetraoxapentadecan-15-oic acid, 1-amino-
663921-15-1
1-amino-3,6,9,12-tetraoxapentadecan-15-oic acid
3-(2-{2-[2-(2-aminoethoxy)ethoxy]ethoxy}ethoxy)propanoic acid
3-(2-{2-[2-(2-amino-ethoxy)-ethoxy]ethoxy}ethoxy)propionic acid
DKUZHSDZSMQOGQ-UHFFFAOYSA-N
3-(2-{2-[2-(2-amino-ethoxy)-ethoxy]-ethoxy}-ethoxy)-propionic acid
15-amino-4,7,10,13-tetraoxapentadecanoic acid
SCHEMBL515661
15-amino-4,7,10,13-tetraoxa-pentadecanoic acid
mfcd11041129
c11h23no6
h2n-peg4-ch2ch2cooh
DTXSID10627909
(peo)4-aminopropionic acid
GS-6313
3-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]propanoic acid
A918138
(peo)4-amino-propionic acid
1-amino-3,6,9,12-tetraoxapentadecan-15-oicacid
SY122326
1-amino-3,6,9,12-tetraoxa-15-pentadecanoic acid
h2n-peg4- ch2ch2cooh
3-amino(peg4)propionic acid
amino-peg4-cooh
(peo)4-amino-propionic acid;h2n-dpeg(4)-cooh;1-amino-3,6,9,12-tetraoxapentadecan-15-oic acid
BCP32999
FT-0775002
3-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy] ethoxy]propionic acid
Q27454167
HY-W021787
nh2-peg4-ch2ch2cooh
CS-0041310
H10621
nh2-peg4-cooh
LCZC399
EN300-1590255
amino-dpeg4-acid
amine-peg4-cooh
3-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]propionicacid
a-amine-?-propionic acid tetraethylene glycol
tetraethylene glycol amino propionic acid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.34 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (16.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
glycine
[no description available]		2.0510alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
glycyl-glycyl-glycine
glycyl-glycyl-glycine : A tripeptide in which three glycine units are linked via peptide bonds in a linear sequence.		2.0510tripeptide zwitterion;
tripeptide
technetium
Technetium: The first artificially produced element and a radioactive fission product of URANIUM. Technetium has the atomic symbol Tc, and atomic number 43. All technetium isotopes are radioactive. Technetium 99m (m=metastable) which is the decay product of Molybdenum 99, has a half-life of about 6 hours and is used diagnostically as a radioactive imaging agent. Technetium 99 which is a decay product of technetium 99m, has a half-life of 210,000 years.		2.0610manganese group element atom
1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid: structure given in first source. DOTA : An azamacrocyle in which four nitrogen atoms at positions 1, 4, 7 and 10 of a twelve-membered ring are each substituted with a carboxymethyl group.		2.0510azamacrocyclechelator;
copper chelator
n-(4-carboxycyclohexylmethyl)maleimide n-hydroxysuccinimide ester
N-(4-carboxycyclohexylmethyl)maleimide N-hydroxysuccinimide ester: used in the preparation of rabbit Fab'-peroxidase conjugates. succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate : An N-hydroxysuccinimide ester derived from 4-(N-maleimidomethyl)cyclohexane-1-carboxylic acid.		2.0510maleimides;
N-hydroxysuccinimide ester
maytansine
Maytansine: An ansa macrolide isolated from the MAYTENUS genus of East African shrubs.. maytansine : An organic heterotetracyclic compound and 19-membered macrocyclic lactam antibiotic originally isolated from the Ethiopian shrub Maytenus serrata but also found in other Maytenus species. It exhibits cytotoxicity against many tumour cell lines.		2.0510alpha-amino acid ester;
carbamate ester;
epoxide;
maytansinoid;
organic heterotetracyclic compound;
organochlorine compound		antimicrobial agent;
antimitotic;
antineoplastic agent;
plant metabolite;
tubulin modulator
ConditionIndicatedRelationship StrengthStudiesTrials
HIV Coinfection
[description not available]		03.5311
HIV Infections
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).		03.5311
Benign Neoplasms
[description not available]		02.4520
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.4520
Glial Cell Tumors
[description not available]		02.0510
Glioma
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)		02.0510
Adenocarcinoma, Basal Cell
[description not available]		02.0510
Adenocarcinoma Of Kidney
[description not available]		02.0510
Cancer of Colon
[description not available]		02.0510
Cancer of Kidney
[description not available]		02.0510
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		02.0510
Carcinoma, Renal Cell
A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.		02.0510
Colonic Neoplasms
Tumors or cancer of the COLON.		02.0510
Kidney Neoplasms
Tumors or cancers of the KIDNEY.		02.0510
Embolism, Pulmonary
[description not available]		02.0610
Blood Clot
[description not available]		02.0610
Pulmonary Embolism
Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS.		02.0610
Thrombosis
Formation and development of a thrombus or blood clot in the blood vessel.		02.0610